Download Files:
Products Details
Product Description
– Oritavancin (LY 333328) is an orally active glycopeptide antibiotic with activity against gram-positive organisms. Oritavancin shows antibacterial effect against multidrug-resistant S. pneumoniae. Oritavancin inhibits cell wall synthesis and disrupts the membrane potential[1][2].
Web ID
– HY-B1831
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C86H97Cl3N10O26
References
– [1]Coyle EA, et al. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2001 Mar;45(3):706-9.|[2]Arhin FF, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008 May;52(5):1597-603.
CAS Number
– 171099-57-3
Molecular Weight
– 1793.10
SMILES
– O[C@@H]1[C@@H](O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@]2(C)NCC3=CC=C(C4=CC=C(Cl)C=C4)C=C3)[C@@H](O[C@H](CO)[C@H]1O)OC5=C(OC6=CC=C([C@H]([C@H]7NC([C@H](NC)CC(C)C)=O)O)C=C6Cl)C=C([C@](NC([C@@H](NC7=O)CC(N)=O)=O)([H])C(N[C@](C8=O)([H])C9=CC%10=C(O)C=C9)=O)C=C5OC%11=CC=C([C@H]([C@](C(N[C@@](C(O)=O)([H])C%12=C%10C(O)=CC(O)=C%12)=O)([H])N8)O[C@@](O[C@@H](C)[C@@H]%13O)([H])C[C@@]%13(N)C)C=C%11Cl
Clinical Information
– Launched
Research Area
– Infection; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Antibiotic;Bacterial
Isoform
– Glycopeptide
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
